Brenig Therapeutics, Inc., a clinical-stage biotech, has initiated its first-in-human study for BT-409, a brain-selective NLRP3 inflammasome inhibitor. The company also shared progress on BT-267, its CNS-optimized LRRK2 inhibitor for Parkinson’s disease.
BT-409 Enters First-in-Human Clinical Testing
BT-409 is a small-molecule, brain-selective NLRP3 inhibitor licensed from Mwyngil Therapeutics.
The compound was discovered and optimized using Brenig’s AI- and machine learning–enabled platform, with emphasis on:
- Central nervous system penetration
- High potency
- Pharmacokinetics suitable for chronic neurological use
Phase 1 Study Design
Brenig has initiated a Phase 1 SAD/MAD study in healthy volunteers.
The trial will evaluate:
- Safety and tolerability
- Pharmacokinetics
- Pharmacodynamic activity
First dosing is expected in early Q1 2026.
What Comes Next?
If Phase 1 is successful, Brenig plans proof-of-concept studies in:
- Multiple sclerosis
- Parkinson’s disease
The program targets neuroinflammation and neurodegeneration via central inflammasome inhibition.
BT-267 Continues Clinical Momentum in Parkinson’s Disease
BT-267 is a highly selective, brain-optimized LRRK2 inhibitor designed to maximize CNS exposure while limiting peripheral effects.
Early clinical data show:
- Favorable pharmacokinetics
- Sustained CNS exposure above predicted LRRK2 IC50 levels
- Encouraging safety and tolerability
Upcoming Studies
Brenig plans to:
- Initiate a Phase 1b study
- Begin start-up activities for a Phase 2 proof-of-concept trial in Parkinson’s disease
Both are targeted for early 2026.
Strategic Focus: CNS-First Drug Design
Both BT-409 and BT-267 reflect Brenig’s strategy of precision CNS drug engineering.
Key design principles include:
- High brain permeability
- Strong target selectivity
- Disease-modifying potential
The company is positioning both programs for efficient clinical translation.
About Brenig Therapeutics
Founded in 2021, Brenig Therapeutics focuses on small-molecule therapies for neurodegenerative diseases.
The company raised $65 million in Series A financing in July 2024, led by NEA, with participation from OrbiMed, Torrey Pines, and others. Brenig’s mission is clear: target core disease mechanisms and move faster from discovery to patients.
